Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383503 | 0.84 | CA2 (0.52) | CYP2A6CYP1A2GSTP1RAB9ANPC1 | |
| SCHEMBL7454647 | 0.82 | GSTP1 (0.60) | CYP2A6CYP1A2GSTP1RAB9ANPC1 | |
| SCHEMBL7286859 | 0.81 | GSTP1 (0.55) | CYP2A6CYP1A2GSTP1MAOBKDM4E | |
| SCHEMBL12947560 | 0.78 | GSTP1 (0.56) | CYP2A6CYP1A2GSTP1RAB9ANPC1 | |
| SCHEMBL15119600 | 0.78 | MAOB (0.53) | GSTP1RAB9ANPC1MAOBMAPT | |
| SCHEMBL5256291 | 0.78 | MCL1 (0.46) | RAB9ANPC1MAOBKDM4EALDH1A1 | |
| SCHEMBL26882761 | 0.77 | GSTP1 (0.55) | CYP2A6CYP1A2GSTP1RAB9ANPC1 | |
| SCHEMBL7450739 | 0.77 | GSTP1 (0.55) | CYP2A6CYP1A2GSTP1KDM4EALDH1A1 | |
| SCHEMBL14007354 | 0.77 | CYP1A2 (0.55) | CYP2A6CYP1A2GSTP1RAB9ANPC1 | |
| SCHEMBL9080103 | 0.76 | ALOX5 (0.44) | CYP2A6CYP1A2RAB9ANPC1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839155-B2 | Organic semiconducting compounds | RAYNERGY TEK INC. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-11839155-B2 | Organic semiconducting compounds | RAYNERGY TEK INC. (TW) | 2023-12-05 | — | — | US | disclosed |
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | disclosed |
| US-7105531-B2 | Tricyclic protein kinase inhibitors | WYETH (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | disclosed |
| US-6638929-B2 | Compounds containing nicotinonitrile rings; anticarcinogenic and -tumor agents; polycystic kidney disease and colonic polyps; antiproliferative agents; angiogenesis inhibitors; restenosis; atherosclerosis; angiofibromas; hemangiomas; | WYETH | 2003-10-28 | — | — | US | disclosed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
| US-5252560-A | Cyclic imide derivatives, compositions and use | GLAXO INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0520573-A1 | Cyclic imide derivatives | GLAXO INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-4351842-A | N-Cyclopropylisoindolines | GLAXO LABORATORIES LIMITED (GB) | 1982-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839155-B2 | Organic semiconducting compounds | OCIAD2, OCIAD1, OSTC | CYP2A6 2279/4885CYP1A2 1006/4885GSTP1 2077/4885 |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | CYP2A6 2854/4885CYP1A2 1255/4885GSTP1 3257/4885 |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | CYP2A6 2618/4885CYP1A2 1076/4885GSTP1 3363/4885 |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | CDK1, CHEK1, ABL1 | CYP2A6 3620/4885CYP1A2 2499/4885GSTP1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.